Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study

OBJECTIVE: Crizotinib has demonstrated promising efficacy in patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) in clinical trials. We conducted this retrospective multicenter study to assess the outcomes of crizotinib therapy in, to our knowledge, a large sam...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Puyuan, Ma, Di, Wang, Qiang, Hao, Xuezhi, Wang, Mengzhao, Wang, Yan, Shan, Li, Xin, Tao, Liang, Li, Liang, Hongge, Du, Yang, Zhang, Zhaohui, Li, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613511/
https://www.ncbi.nlm.nih.gov/pubmed/31354217
http://dx.doi.org/10.21147/j.issn.1000-9604.2019.03.10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613511/
https://www.ncbi.nlm.nih.gov/pubmed/31354217
http://dx.doi.org/10.21147/j.issn.1000-9604.2019.03.10

Ejemplares similares